The present tool is preferably intended for health professionals who are not specialized in allergy. The information is for reference purposes and therefore does not replace the judgment of the professional and should be used only as a decision aid. The tool, developed through a systematic approach, is supported by the scientific literature as well as by the experiential knowledge of Quebec experts.

For more details, click here.

REMEMBER THAT...

- Real penicillin allergies are infrequent. For more information click here;
- Some viral infections combined with an antibiotic intake (e.g., amoxicillin) result in cutaneous eruptions that may be misleading for allergy diagnostics, especially in children;
- Too many patients are falsely labeled as “allergic” to penicillins and this may lead to the prescription of broad-spectrum antibiotics that trigger more adverse effects.

KEY ELEMENTS TO IDENTIFY & EVALUATE THE SEVERITY OF THE INITIAL REACTION

1. What is the patient’s allergy status?
2. What was the antibiotic of the class of penicillins that could be involved?
3. How much time has elapsed between the antibiotics intake and the reaction?
4. What were the key clinical manifestations, symptoms or impairments observed?
   a. in case of a cutaneous manifestations, how was the severity?
   b. did the reaction have any others severity criteria?

→ Any element of the clinical history that suggests the possibility of an immediate or severe delayed reaction requires an extra level of vigilance when re-administering a beta-lactam.

→ In the presence of severity criteria (e.g., an organ or mucosal impairment, desquamation, etc.), it is advisable to obtain consultation with specialized services.

DECISION MAKING REGARDING THE ADMINISTRATION OF A NEW BETA-LACTAM

5. What are the elements to consider when re-administering a beta-lactam?

→ The probability that the initial reaction is of an allergic nature and the severity of it;

→ The risk of cross reaction between the indicated beta-lactam and the penicillin concerned, which may increase when the two antibiotics share similar structural and physicochemical properties (Table 1).

6. Can I prescribe a beta-lactam? If yes, what would be the conditions of administration?

→ Engage the patient or his family in the decision.

PATIENT MONITORING AFTER THE ADMINISTRATION OF THE NEW BETA-LACTAM

7. What are the actions to be taken after the administration of the new beta-lactam in case of penicillin allergy?

→ Clearly document the reaction (allergic reaction or antibiotic tolerance);

→ If allergic reaction, complete the declaration form for a new drug allergy reaction.
For more details, click on the underlined words.

**ASSESS THE SEVERITY OF THE INITIAL REACTION**

**DECISION MAKING CONCERNING THE CHOICE OF BETA-LACTAM AND CONDITIONS OF ADMINISTRATION**

**I PRESCRIBE SAFELY**

- **Carbapenems**
- **Cephalosporins DIFFERENT**
- **Cephalosporins SIMILAR** if the history of allergy does not suggest an immediate reaction...

   If in doubt about the possibility of an immediate reaction...
   An observation period of one hour after the administration of the first dose under the supervision of a health professional could be advised according to the clinician's judgement.

**I PRESCRIBE WITH CAUTION**

- **Penicillines**

   The 1st dose should always be administered under medical supervision.

   If history of:
   - Immediate reactions - a drug provocation test should be performed;
   - Delayed reactions - the patient or his family should be advised about the risk of using the antibiotics.

**I AVOID PRESCRIBING**

- **Beta-lactam**

   Privilege another class of antibiotic. If strong indication of a beta-lactam, obtain a consultation with specialized services.

---

For more information on similar cephalosporins and different penicillins, see Tables 1 and 2.

---

1. Immediate reaction (type I or IgE-mediated): usually occurs within one hour after taking the first dose of an antibiotic.
2. Delayed reaction (types II, III and IV): may occur at any time from one hour after administration of a drug.
3. Anaphylaxis without shock or intubation: requires an extra level of vigilance.
4. Delayed skin reactions and serum sickness-like reactions that occur in children on antibiotic therapy are generally non-allergic and may be of viral origin.
5. Without recommendations for other beta-lactams.
6. Use sparingly with increasing prevalence of carbapenemase-producing enterobacteria.
### 1. WHAT IS THE ALLERGY STATUS OF THE PATIENT?

<table>
<thead>
<tr>
<th>Penicillin allergy is <strong>CONFIRMED...</strong></th>
<th>Penicillin allergy is <strong>SUSPECTED...</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>If valid and compliant diagnostic tests (skin test or drug provocation test) have been performed by a doctor.</td>
<td>If a patient reports a history of penicillin allergy that has never been confirmed by diagnostic tests.</td>
</tr>
</tbody>
</table>

**REMEMBER THAT...**
- Atopy and food allergies are not risk factors for drug allergy;
- People with a family history of drug allergy are no more likely to respond in their turn to the concerned drugs.
IDENTIFY...
The antibiotic (s) suspected or evoked by the patient:
- What was the name of the antibiotic that could be concerned?
- What was the dose, route of administration and duration of treatment?

VERIFY IF...
- Since the so-called allergic episode the patient has resumed taking without problem and without reaction:
  - the same antibiotic: so he is not allergic to this antibiotic;
  - another antibiotic in the penicillin class: this does not exclude the possibility that he is still allergic to the antibiotic that caused the initial reaction (e.g., a patient may be allergic to piperacillin/tazobactam, but tolerate amoxicillin).
- The patient has already undergone allergy testing (skin test or drug provocation test) for the concerned penicillin or for another beta-lactam.

CAUTION
In patients with a chronic disease and who are frequently exposed to antibiotics (e.g., those with cystic fibrosis), a higher level of alertness than the general population should be maintained since this is an important risk factor for the development of a drug allergy, especially to beta-lactams.
3. HOW MUCH TIME HAS ELAPSED BETWEEN THE ANTIBIOTIC INTAKE AND THE REACTION?

IDENTIFY...

The chronology of the obtained reaction:
- In the patient’s recollection, how old he was at the moment of reaction?
- How much time has elapsed between the antibiotic intake and the reaction?
  - Less than an hour after taking the **first dose** of the antibiotic?
  - If it took place during the treatment, how many days after the beginning of treatment?
  - If it took place after the end of treatment, how many days after the end of treatment?

REMEMBER THAT...

In most people, time is likely to remedy the confirmed allergy to penicillins (e.g., more than half of patients will no longer be allergic to penicillin after 10 years).

In order to find help with differentiating the type of reaction, I can consult the following table or the interactive tool.

<table>
<thead>
<tr>
<th>Type of allergic reaction*</th>
<th>Immediate reaction</th>
<th>Delayed reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Type I</td>
<td>Type II</td>
</tr>
<tr>
<td>Clinical examples</td>
<td>• Anaphylaxis</td>
<td>• Serum sickness</td>
</tr>
<tr>
<td></td>
<td>• Angioedema</td>
<td>• Palpable purpura</td>
</tr>
<tr>
<td></td>
<td>• Bronchospasm</td>
<td>• Vasculitis</td>
</tr>
<tr>
<td></td>
<td>• Hypotension</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Urticaria</td>
<td></td>
</tr>
<tr>
<td>Time of onset of symptoms</td>
<td>From a few minutes</td>
<td>From a few hours</td>
</tr>
<tr>
<td>(post-exposure to the drug)</td>
<td>to an hour (can</td>
<td>to several days</td>
</tr>
<tr>
<td></td>
<td>take up to 6 hours)</td>
<td>(can take up to 6 weeks for the DRESS)</td>
</tr>
</tbody>
</table>

* Adapted from Gell and Coomb classification.

CAUTION

Any reaction occurring less than one hour after the first dose of the antibiotic suggests an IgE-mediated allergy and could therefore cause an **anaphylactic reaction** during re-exposure (the risk of an anaphylactic reaction is very low).
4. WHAT WERE THE MAIN SIGNS, SYMPTOMS OR IMPAIRMENTS OBSERVED?

In order to find help with differentiating the type of reaction, I can consult the following table or the interactive tool.

IDENTIFY...

The different types of impairments which were observed or reported:

- Dermal (e.g., bubbles, pustules, urticaria);
- Gastrointestinal (e.g., vomiting, severe diarrhea);
- Hematologic (e.g., lymphadenopathy, anemia, eosinophilia, lymphocytosis);
- Hepatic (e.g., increased transaminases);
- Renal (e.g., proteinuria, increased urea and/or creatinine);
- Respiratory (e.g., difficulty breathing, bronchospasm, dyspnea, dysphonia, stridor);
- Systemic (e.g. shock, general impairment, hypotension, fever> 38.0 °C).

REMEMBER THAT...

- In children, some clinical presentations (e.g., severe urticaria with arthralgia) are often misdiagnosed as a serum sickness-like reaction.
- Some symptoms that appear after taking antibiotics may suggest intolerance rather than allergy (e.g., amoxicillin-clavulanate diarrhea).

Back to the cover page
4. WHAT WERE THE MAIN SIGNS, SYMPTOMS OR IMPAIRMENTS OBSERVED?

a. How severe were cutaneous impairments, if any?

VERIFY IF...

Did the reaction present a cutaneous manifestation? If so, how severe was the observed or the reported impairment?

- How long did it last?
- Whether there has been desquamation?
- Whether there was associated pruritus?
- Was it more like maculopapular rash or hives?

In order to find help with differentiating the type of reaction, I can consult the following table or the interactive tool.

<table>
<thead>
<tr>
<th>Distinction</th>
<th>Immediate allergic cutaneous reaction</th>
<th>Delayed allergic cutaneous reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical examples</td>
<td>NON-SEVERE</td>
</tr>
<tr>
<td>Time of onset of symptoms</td>
<td>Urticaria</td>
<td>Rash</td>
</tr>
<tr>
<td>Duration of the reaction</td>
<td>Generally &lt;1 hour after taking the 1st dose of the antibiotic</td>
<td>Usually after a few days of treatment</td>
</tr>
<tr>
<td>Type of lesions and its characteristics</td>
<td>Rash</td>
<td>Macular lesions without relief and/or raised papular lesions</td>
</tr>
<tr>
<td>Distribution of lesions</td>
<td>Location is limited to only one part of the body or may extend over several regions (generalized)</td>
<td>Preferred localization and anatomical progression is generally from the trunk to the limbs (depends on the syndrome and the type of lesions)</td>
</tr>
<tr>
<td>Associated pruritus</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Associated edema</td>
<td>Usually localized and superficial angioma of the dermis without epidermal change (no scales, no vesicles, etc.)</td>
<td>None</td>
</tr>
<tr>
<td>Other characteristics</td>
<td>Usually disappears without leaving a trace on the skin and without desquamation</td>
<td>Usually disappears without desquamation and is not accompanied by any other symptom</td>
</tr>
</tbody>
</table>

Legend:
1. In the case of pathognomonic urticaria detected in the questionnaire, a duration of more than 48 hours following the discontinuation of the drug generally excludes a type I allergy.
2. When the urticaria is deeper, the lesions sit in the deep dermis and hypodermis. It is then an angioedema or an acute subcutaneous urticaria.
4. WHAT WERE THE MAIN SIGNS, SYMPTOMS OR IMPAIRMENTS OBSERVED?

b. Did the reaction have any seriousness criteria?

**IDENTIFY...**
Severity criteria, signs, symptoms or important impairments:
- Has the potentially allergic reaction led the patient to emergency or intensive care?
- Did the reaction require treatment? If yes, what was the prescribed treatment and what was the answer?

**CAUTION**
The presence of only one of these signs, symptoms or impairments is sufficient to require an in-depth evaluation or a consultation with the specialized services.

<table>
<thead>
<tr>
<th>TYPE OF IMPAIRMENT</th>
<th>SEVERITY CRITERIA</th>
<th>Immediate reaction</th>
<th>Delayed reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Signs, symptoms and impairments</td>
<td>Type I</td>
<td>Type II</td>
</tr>
<tr>
<td></td>
<td>Anaphylaxis</td>
<td>Severe</td>
<td>Very severe</td>
</tr>
<tr>
<td>Systemic</td>
<td>Shock with or without intubation</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>General condition impairment</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Fever &gt; 38.0 °C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous</td>
<td>Painful skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Petechia and palpable purpura</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mucosal impairment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vesicles, bubbles, pustules</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Desquamation of the skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Complete skin detachment (ulcer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% body surface area reached</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edema</td>
<td>Angioedema (lips, tongue, throat, face)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Facial edema</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Dyspnea</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Dysphonia</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Bronchospasm (or wheezing)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Stridor</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hematological</td>
<td>Urinary eosinophilia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphocytosis and/or atypical lymphocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphadenopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anemia</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Significant increase in CRP (&gt; 100 mg/L) or ferritin (&gt; 500 μg/L)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Other</td>
<td>Joints impairment (arthritis, arthralgia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal impairment (↑ proteinuria, urea and creatinine)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatic impairment (↑ transaminases)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Who are the patients who could benefit from specialist consultation and allergic assessment?

For situations where accessibility to an allergist is more difficult, the following criteria could be used to guide an application to specialized services:

Immediate allergic reactions (IgE-mediated)
- Patient who has had a suspected anaphylactic reaction, whose history is poorly documented or of unknown etiology (e.g., any unexplained anaphylactic reaction when beta-lactam has been co-administered with several other agents).

Very severe delayed allergic reactions
- Patient with a history (suspected or confirmed) of very severe delayed reactions such as DRESS syndrome, SJS / TEN or AGEP.

Allergic reactions in a special patients subgroup
- A patient with a history (suspected or confirmed) of allergic reactions to beta-lactam antibiotics (immediate or delayed) if:
  - he is likely to use this type of antibiotic frequently (e.g., patients with recurrent bacterial infections or with COPD with frequent secondary infections, cystic fibrosis or an immune deficiency);
  - he requires treatment for a disease or condition that can only be treated with beta-lactam (e.g., neurosyphilis).
- A pediatric patient with a history (suspected or confirmed) of allergic reactions to beta-lactam antibiotics (immediate or delayed) so that he is not incorrectly labelled allergic and so that he can access the best therapeutic tools.
- A polymedicated patient (e.g., elderly person) with a history (suspected or confirmed) of allergic reactions to beta-lactam antibiotics (immediate or delayed) who is at a higher risk of drug interactions or in whom safe options are more limited (e.g., patient who is currently on medications that prolong the QT interval).

Multiple allergy
- Patient with a history of allergic reactions to beta-lactams and at least one other class of antibiotics, specifically patients with allergies to:
  - penicillins and quinolones;
  - penicillins and macrolides;
  - penicillins and trimethoprim-sulfamethoxazole.

REMEMBER THAT...
Upon reception of the diagnosis following a consultation with the specialized services, the complete information on the drug allergy should be updated in the patient’s medical record or in a place reserved for this purpose in the computerized/electronic files (EHR or DME) and minimally included in the following documents and databases:
- Consultation report for the attending physician;
- Pharmacological record (hospital or community);
- Medical records service of the hospital.
5. WHAT ARE THE RISKS ASSOCIATED WITH THE RE-EXPOSURE TO A BETA-LACTAM?

General population

On 1000 persons with a HISTORY of allergy to penicillins

Only 100 of them will have an allergy CONFIRMED (10%)

In children, the frequency of a real allergy is lower (less than 6%). The majority of the reactions observed are usually non-severe delayed cutaneous eruptions.

Of the 100 persons who are really allergic to penicillin, some would react to the administration of another beta-lactam...

CEPHALOSPORIN SIMILAR*

10-15 people would react to a cephalosporin, if it shares with the concerned penicillin SIMILAR* structural and physicochemical properties.

CEPHALOSPORIN DIFFERENT

1 to 2 people would react to a cephalosporin, if it shares with the concerned penicillin DIFFERENT* structural and physicochemical properties.

CARBAPENEM

Less than 1 person would react to a carbapenem.

Remarks: The figures are presented for reference only. They are supported by data from the scientific literature and are linked to several guidelines.

Legend:
* Similarities between penicillins and cephalosporins were assessed for structural properties (R1 side chain) and physicochemical properties (e.g., pKa, charge, polarity, hydrophobicity, hydrogen bond donor/acceptor, etc.).
For more information, click here.

6. IN PRIMARY CARE, WHAT IS THE PROCESS TO BE FOLLOWED AND THE NECESSARY PREREQUISITES TO PERFORM DRUG PROVOCATION TESTS IN THE CASE OF PATIENTS WITH A PRIOR HISTORY OF IGE-MEDIATED (TYPE I) REACTION?

WHAT YOU NEED TO KNOW...

**DRUG PROVOCATION TESTS**

- Drug provocation tests must be performed under medical supervision, by trained personnel and in care settings equipped with resuscitation equipment.
- Optimally, the administration of the antibiotic should be done in two steps:
  - 10% of the total dose (a delay of 30 minutes* is recommended before the administration of the 2nd dose);
  - 90% of the total dose.
- A patient observation period of **60 minutes** after the last dose is advised.

* regardless of the route of administration (oral or injectable)

**CAUTION**

- A 3-step procedure with 60-minute intervals starting at 1% of the total dose is desirable for patients with a history of anaphylaxis.
- Drug provocation tests are contraindicated in the cases of very severe allergic reactions (e.g., anaphylactic shock, SJS / TEN, DRESS, AGEP).
- A verbal consent from the patient should be obtained and documented on file (or as per the terms of each facility).
- In the case of a delayed allergic reaction, late effects (usually an itchy eruption) may occur within days after the test (it is important to advise the patient).
7. WHAT MEASURES ARE TO BE TAKEN AFTER THE ADMINISTRATION OF A NEW BETA-LACTAM TO A PATIENT WHO HAS A SUSPECTED OR CONFIRMED PENICILLIN ALLERGY?

In case of allergic reaction:

- Stop the antibiotic administration and treat the reaction as needed.*
- Update the complete information on drug allergy status in, at least, the following document and databases:
  - Patient’s medical record or in a designated area for this purpose in computerized/electronic files (electronic health record system (EHR) such as Cristal net or electronic medical file (DME));
  - Request for consultation with the medical specialist or consultation report destined to the attending physician;
  - Pharmacological record (hospital or community care);
  - Medical records service of the hospital.
- Clearly inform the patient about his diagnosis, his type of reaction, and the name of the suspected drug.
- Assess the need for consultation with specialized services.

* If necessary, consult the clinical criteria for the diagnosis of anaphylaxis.

If there is an antibiotic tolerance or an adverse effect:

Clearly document the observed reaction:

- In the patient’s medical record;
- In a place reserved for this purpose in computerized/electronic files.
**CLINICAL CASES**

The clinical cases are provided here for guidance and do not replace the professional’s judgment. They must be used as a decision support tool only.

---

1. **History of a delayed isolated non-severe skin reaction in children**
   - 3-year-old child with community-acquired pneumonia in need of an antibiotic.
   - Developed almost 2 years ago, a non-immediate maculopapular rash after 3 days of drug regimen with amoxicillin to treat acute otitis media.

   **Remember that…**
   in children, some viral infections combined with an antibiotic (e.g., amoxicillin) result in skin eruptions that may be misdiagnosed as allergic.

2. **History of a recent isolated, non-severe, delayed cutaneous reaction in adults**
   - 40-year-old adult with group A streptococcal pharyngitis-tonsillitis in need of an antibiotic.
   - Developed 5 years ago a non-immediate maculopapular rash especially in the trunk after ± 5 days of drug regimen with amoxicillin to treat acute bacterial rhinosinusitis.

3. **History of a severe immediate reaction (IgE-mediated) in adults**
   - A 66-year-old adult in need of an antibiotic because of the acute bacterial rhinosinusitis with persistent symptoms for more than 10 days.
   - Developed 10 years ago a generalized urticaria with bronchospasm (probable anaphylaxis) less than one hour after the first intake of penicillin V, which was administered to treat pharyngitis-tonsillitis.

---

**Can I prescribe a beta-lactam?**
**If yes, what would be the conditions of administration?**

<table>
<thead>
<tr>
<th>I PRESCRIBE SAFELY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefprozil or cefuroxime axetil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I PRESCRIBE WITH CAUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin or Amoxicillin-Clavulanate</td>
</tr>
<tr>
<td>If I opt for one of these options...</td>
</tr>
<tr>
<td>The 1st dose should always be administered under medical supervision.</td>
</tr>
<tr>
<td>The patient or family should be advised of the risk of recurrence.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I AVOID PRESCRIBING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin V and Amoxicillin</td>
</tr>
</tbody>
</table>

---

**Can I prescribe a beta-lactam?**
**If yes, what would be the conditions of administration?**

<table>
<thead>
<tr>
<th>I PRESCRIBE WITH CAUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefixime or cefuroxime axetil</td>
</tr>
<tr>
<td>If I opt for one of these options...</td>
</tr>
<tr>
<td>The 1st dose should always be administered under medical supervision.</td>
</tr>
<tr>
<td>The patient or family should be advised of the risk of recurrence.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I AVOID PRESCRIBING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin-Clavulanate</td>
</tr>
</tbody>
</table>

---

**Can I prescribe a beta-lactam?**
**If yes, what would be the conditions of administration?**

<table>
<thead>
<tr>
<th>I PRESCRIBE WITH CAUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalexin</td>
</tr>
<tr>
<td>If I opt for one of these options...</td>
</tr>
<tr>
<td>The 1st dose should always be administered under medical supervision.</td>
</tr>
<tr>
<td>The patient or family should be advised of the risk of recurrence.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I AVOID PRESCRIBING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin V and Amoxicillin</td>
</tr>
</tbody>
</table>

---

**Can I prescribe a beta-lactam?**
**If yes, what would be the conditions of administration?**

<table>
<thead>
<tr>
<th>I PRESCRIBE WITH CAUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefixime or cefuroxime axetil</td>
</tr>
<tr>
<td>If I opt for one of these options...</td>
</tr>
<tr>
<td>The 1st dose should always be administered under medical supervision.</td>
</tr>
<tr>
<td>Since there is an antecedent of immediate reaction, a drug provocation test should be performed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I AVOID PRESCRIBING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin-Clavulanate</td>
</tr>
</tbody>
</table>

---

Back to the algorithm
# LEGEND

<table>
<thead>
<tr>
<th>Icon</th>
<th>Description</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>🔄</td>
<td>VERIFY IF...</td>
<td>Sets of important elements to check or identify during the clinical examination.</td>
</tr>
<tr>
<td>🔍</td>
<td>IDENTIFY...</td>
<td>Administration without special precautions.</td>
</tr>
<tr>
<td>🔄</td>
<td>REMEMBER THAT...</td>
<td>Reminder of relevant information that may assist the diagnostic process.</td>
</tr>
<tr>
<td>🛑</td>
<td>WHAT YOU NEED TO KNOW...</td>
<td>Information which is relevant and necessary for optimal patient management.</td>
</tr>
<tr>
<td>🚨</td>
<td>CAUTION</td>
<td>Zones of vigilance or special attention to be paid during the clinical evaluation.</td>
</tr>
</tbody>
</table>

## ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGEP</td>
<td>acute generalized exanthematous pustulosis,</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease,</td>
</tr>
<tr>
<td>DCI</td>
<td>dossier clinique informatisé,</td>
</tr>
<tr>
<td>DMÉ</td>
<td>dossiers médicaux électroniques,</td>
</tr>
<tr>
<td>DRESS</td>
<td>drug reaction with eosinophilia and systemic symptoms,</td>
</tr>
<tr>
<td>EHR</td>
<td>electronic health record system,</td>
</tr>
<tr>
<td>Rash</td>
<td>maculopapular rash (also known as maculopapular eruption),</td>
</tr>
<tr>
<td>SJS</td>
<td>Stevens–Johnson syndrome,</td>
</tr>
<tr>
<td>TEN</td>
<td>toxic epidermal necrolysis.</td>
</tr>
</tbody>
</table>

## REFERENCES

- INESSS 2017, ADDENDA Avis sur la standardisation des pratiques relatives aux allergies aux béta-lactamines.
- INESSS 2017, Méta-analyse sur l'évaluation du risque de réactions croisées aux céphalosporines et carbapénèmes chez des patients avec une allergie CONFIRMÉE aux pénicillines.
The content of the documents on penicillin allergy has been developed, written and edited by the Institut national d'excellence en santé et en services sociaux (National Institute of Excellence in Health and Social Services) (INESSS).

It is derived from the Avis sur la standardisation des pratiques relatives aux allergies aux bêta-lactamines et son Addenda (Notice on the Standardization of practices regarding beta lactam allergies and its Addendum). These documents are available here.

Project team
Authors
Geneviève Robitaille, Ph. D.
Fatiha Karam, Ph. D.

Scientific coordination
Mélanie Tardif, Ph. D.

Scientific leadership
Sylvie Bouchard, B. Pharm., D.P.H., M. Sc., M.B.A.

Knowledge transfer team
Renée Latulippe, M. A., scientific coordinator
Mélanie Samson, Ph. D., scientist-practitioner
Amina Yasmine Acher, M. A., graphic designer

Advisory committee
Philippe Bégin, M. D., Ph. D., FRCPC, allergist-immunologist, Sainte-Justine University Hospital Center and University Hospital of Montreal; associate clinical professor, University of Montreal, Montreal, Quebec.

Marie-Dominic Breault, M. D., emergency physician, Integrated Health and Social Services Center (CISSS), Gaspésie-Iles-de-la-Madeleine, Quebec.

Jonathan Lacombe-Barrios, M. D., FRCPC, allergist-immunologist, Sainte-Justine University Hospital Center, professor, department of pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec.

Isabelle Levasseur, nurse practitioner, GMF Laval (UMF of Cité-de-la-Santé, Laval), Quebec.

Hélène Paradis, B. Pharm., M. Sc., pharmacist; chief of the pharmacy department of the Integrated Health and Social Services Center (CIUSSS) of the West Island of Montreal, Montreal, Quebec.

Matthieu Picard, M. D., FRCPC, allergist-immunologist, Maisonneuve-Rosemont Hospital, assistant clinical professor, University of Montreal, Montreal, Quebec.

Frédéric Poitras, B. Pharm., community pharmacist; lecturer, Faculty of Pharmacy, Laval University, Quebec, Quebec.

Participants in the expanded consultation (other than Advisory Committee members)
Cybèle Bergeron, M. D., FRCPC, pediatrician-infectiologist, University Hospital of Sherbrooke, Sherbrooke, Quebec.

Luc Bergeron, B. Pharm, pharmacist and clinical professor, University Hospital of Quebec - Laval University, Quebec, Quebec.

Michel Cauchon, M. D., family physician, Maizerets family medicine unit; professor, Faculty of Medicine, department of family medicine and emergency medicine, Laval University, Quebec, Quebec.

Sylvain Couture, M. D., family doctor, in private practice (Quebec).

Jean-Philippe Drolet, M. D., FRCPC, allergist-immunologist, pediatrician, University Hospital of Quebec - Laval University, Quebec, Quebec.

Rémi Gagnon, M. D., FRCPC, allergist-immunologist and chief of the allergy and immunology department at the Clinic of the University Hospital of Quebec, Laval University, Quebec City, Quebec; president of the Association of Allergists and Immunologists of Quebec (AAIQ).

Dany Harvey, M. D., FRCPC, pediatrician, Carrefour de santé de Jonquière, Saguenay-Lac St-Jean, Quebec.

Allison Kukhta, M. D., FRCPC, allergist-immunologist, pediatrician, Vallée-de-l’Or Health and Social Services Center, Val-d’Or, Quebec.

Marc Lebel, M. D., FRCPC, pediatrician-infectiologist at the University Hospital of Sainte-Justine and associate clinical professor, department of pediatrics, University of Montreal, Montreal, Quebec.

Chantal Lemire, M. D., FRCPC, pediatric clinical allergist-immunologist, Estrie Integrated Center for Health and Social Services - Sherbrooke University Hospital Center, Sherbrooke, Quebec.

Nicole Le Saux, M. D., FRCPC, pediatrician-infectiologist, Children’s Hospital of Eastern Ontario (CHEO) research associate professor, Faculty of Medicine, University of Ottawa, Ottawa, Ontario.

Pierre-Claude Poulin, M. D., FRCPC, pediatrician, Integrated Health and Social Services Center of Chaudière-Appalaches, Beauce sector, St-Georges (Quebec).

Audrey Vachon, B. Pharm, M. Sc., pharmacist, University Institute of Cardiology and Pulmonology of Quebec, Quebec City, Quebec; clinical professor, Faculty of Pharmacy, Laval University, Quebec, Quebec.